Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The EMBOL-AF Global Registry provides comprehensive data on stroke and systemic embolism post-atrial fibrillation ablation, highlighting incidence, timing, risk factors, and procedural impacts alongside evolving ablation strategies and long
Extremely high NT-proBNP levels in hospitalized patients often indicate infection rather than heart failure, with a high mortality risk; interpretation requires comprehensive clinical context.
The ULYSSES trial demonstrates that ultrasound-guided femoral venous puncture markedly lowers vascular access complications compared to conventional palpation-guided techniques in patients undergoing atrial fibrillation ablation, enhancing
This trial evaluated whether atrioventricular node ablation improves outcomes of cardiac resynchronization therapy in heart failure patients with permanent atrial fibrillation, finding no significant benefit over medical rate control.
MTMR4 minor allele homozygosity influences arrhythmic risk oppositely in LQT1 and LQT2, providing critical insights for personalized risk stratification in long QT syndrome patients.
Left atrial mechanical dysfunction, particularly atrial electromechanical dissociation and impaired left atrial strain contraction, forecasts increased cerebrovascular events in transthyretin amyloid cardiomyopathy patients even in sinus rh
The EXCALIBUR study reveals significant arrhythmia incidence in cardiac amyloidosis (CA), highlighting subtype-specific arrhythmic profiles linked to myocardial amyloid burden, guiding risk stratification and management.
This study reveals that lifelong genetic differences in LDL cholesterol levels do not significantly affect the risk of venous thromboembolism (VTE), suggesting LDL-C may not be a major causal factor in VTE development.
This large nationwide study demonstrates that coronary CTA-derived FFR-CT strongly predicts future myocardial infarction, cardiovascular death, and revascularization, independent of traditional risk factors and stenosis severity, with a thr
This article examines the real-world safety and efficacy of the extravascular implantable cardioverter defibrillator (EV-ICD) over 1 year, demonstrating effective arrhythmia management and an acceptable safety profile in a large, global pat
Sotatercept improves right heart mechanics in patients with pulmonary arterial hypertension by decreasing right ventricular afterload and contractility in a balanced manner, enhancing right ventricular free wall function and right atrial pe
A phase 2 randomized trial found that ilofotase alfa did not significantly reduce kidney injury or improve outcomes in high-risk patients undergoing on-pump cardiac surgery, though it was safe and well tolerated.
A nationwide survey of hospitalists reveals varied beliefs regarding treatment thresholds and approaches for asymptomatic elevated blood pressure in hospitalized patients, highlighting clinical uncertainty and practice variation.
Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced ab
A gene-specific, risk-based screening algorithm for relatives with titin-truncating variants optimizes monitoring intervals from 1 to 5 years, improving safety and resource use in dilated cardiomyopathy surveillance.
The SUSTAIN-IT study reveals variable improvements in health-related quality of life over two years following heart transplantation or long-term mechanical circulatory support in older heart failure patients, highlighting important consider
This study identifies plasma proteomic signatures linked to clonal hematopoiesis driver mutations and develops a proteomic risk score that independently predicts adverse clinical outcomes in heart failure with preserved ejection fraction (H
This study evaluates risk factors for intracranial haemorrhage after tenecteplase fibrinolysis in STEMI patients, developing a prediction model highlighting age, blood pressure, sex, weight, and dose interactions as key determinants.
This study reveals that lipid profiles paradoxically worsen during the early remission phase after curative surgery for Cushing’s syndrome, highlighting a critical window for cardiovascular risk and targeted intervention.
A clinician-focused summary of the 2026 ACC Scientific Statement on gene editing for cardiovascular disease, highlighting indications, recommendations, safety monitoring, ethical issues, and practical steps for integrating these therapies i
Open language-specific specialty feeds and department pages.